Kodiak Sciences Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KOD | IDYA | SRZN | KRYS | OCUL | ROIV | |
|---|---|---|---|---|---|---|
| Market cap | 6.24B | 3.48B | 291.02M | 9.83B | 1.66B | 24.99B |
| P/E (TTM) | — | — | — | 41.6 | — | — |
| Forward P/E | -28.9 | -9.0 | -5.9 | 35.8 | -5.1 | -20.1 |
| Price/book | 101.9 | 2.9 | -1.3 | 7.2 | 3.2 | 5.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +760.95% | +34.89% | +114.83% | +79.50% | −36.37% | +118.63% |
| Today | −0.61% | −0.14% | −16.60% | +0.14% | +0.27% | −2.40% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KOD news ›Kodiak Sciences Inc. (KOD) Presents at American Academy of Ophthalmology Conference 2026 - Slideshow
Seeking Alpha The following slide deck was published by Kodiak Sciences Inc. in conjunction with this event.
HC Wainwright & Co. maintains Buy rating on Kodiak Sciences, $126 price target
HC Wainwright & Co. maintained their Buy rating on Kodiak Sciences's stock with a price target of $126.00. The price target implies an upside of 26.2% from the Oct 9 close of $99.87. Positive Clinical Trial Results: The successful Phase 3…
Kodiak Sciences Rises as Investors Focus on Fresh Clinical Visibility After Phase 3 Win
Kodiak Sciences (KOD) is up 6.4% today. Here is some analysis on what might have caused this price movement. Kodiak Sciences, SEC, Yahoo Finance $KOD insiders have traded $KOD stock on the open market 32 times in the past 6 months. Of…
AAO 2026: Kamuvudine K8 slows geographic atrophy growth in phase 2
Ophthalmology Times The intraocular inflammasome inhibitor kamuvudine K8 (Inflammasome Therapeutics) reduced geographic atrophy (GA) lesion growth by 54% over 6 months at the 0.7-mg dose in a phase 2 trial, according to Liangbo Shen, MD, a…
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology Times, Modern Retina, Ophthalmology Times Europe, and Optometry Times. At the…
KALA BIO (NASDAQ:KALA) Stock Price Down 0.9% – What’s Next?
Posted by Tristan Rich on Oct 10th, 2026 Shares of KALA BIO, Inc. (NASDAQ:KALA – Get Free Report) dropped 0.9% during mid-day trading on Friday. The stock traded as low as $0.2860 and last traded at $0.2940. 285,090 shares traded hands…
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
Kodiak Sciences (KOD) will present clinical data across three development programs at AAO 2026 in New Orleans, October 9–12, 2026. Kodiak Sciences (KOD) will present clinical data across three development programs at AAO 2026 in New…
All Transcripts on Kodiak Sciences Inc. (KOD)
Find all the latest transcripts on Kodiak Sciences Inc. Transcripts Kodiak Sciences Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
Kodiak Sciences Inc. : Insider Transactions
Follow insider transactions on Kodiak Sciences Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Kodiak Sciences Inc. Biotechnology & Medical Research Latest insider…
Kodiak Sciences Inc.(NasdaqGM: KOD) dropped from Russell 3000 Value Benchmark
Kodiak Sciences Inc. dropped from Russell 3000 Value Benchmark... Biotechnology & Medical Research Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell 3000 Value Benchmark Latest news about Kodiak Sciences Inc. Chart Kodiak Sciences…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com9
-
stocktitan.net3
-
themarketsdaily.com3
-
gurufocus.com2
-
jobbersworld.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 34 articles, not a forecast.